SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

30 May 2022 Evaluate
A decrease of about -64.43% in the sales to Rs. 609.19 millions was observed for the quarter ended March 2022. The sales stood at Rs. 1712.87 millions during the similar quarter previous year.Net profit of the cmpany stood at Rs. 90.59 millions for the quarter ended March 2022 a decline of -59.22% from Rs. 222.13 millions  in the same quarter last year.Operating profit Margin for the quarter ended March 2022 slipped to -38.61% as compared to 423.97% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 609.19 1712.87 -64.43 5198.74 5631.78 -7.69 5198.74 5631.78 -7.69
Other Income 4.26 13.03 -67.31 51.98 34.53 50.54 51.98 34.53 50.54
PBIDT -38.61 423.97 -109.11 1196.83 1245.63 -3.92 1196.83 1245.63 -3.92
Interest 43.41 25.48 70.37 188.75 111.62 69.10 188.75 111.62 69.10
PBDT -82.02 398.49 -120.58 1008.08 1134.01 -11.10 1008.08 1134.01 -11.10
Depreciation 79.72 55.41 43.87 321.52 222.82 44.30 321.52 222.82 44.30
PBT -161.74 343.08 -147.14 686.56 911.19 -24.65 686.56 911.19 -24.65
TAX -252.33 120.95 -308.62 6.18 301.55 -97.95 6.18 301.55 -97.95
Deferred Tax -221.54 65.49 -438.28 -143.02 141.09 -201.37 -143.02 141.09 -201.37
PAT 90.59 222.13 -59.22 680.38 609.64 11.60 680.38 609.64 11.60
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) -6.34 24.75 -125.61 23.02 22.12 4.09 23.02 22.12 4.09

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×